Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Seres Therapeutics (MCRB) over the last 6 years, with Q1 2025 value amounting to $8.7 million.

  • Seres Therapeutics' Shares Outstanding (Diluted Average) rose 1929.73% to $8.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 1929.73%. This contributed to the annual value of $155.4 million for FY2024, which is 2140.37% up from last year.
  • Latest data reveals that Seres Therapeutics reported Shares Outstanding (Diluted Average) of $8.7 million as of Q1 2025, which was up 1929.73% from $155.4 million recorded in Q4 2024.
  • Seres Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $155.4 million during Q4 2024, with a 5-year trough of $7.3 million in Q1 2024.
  • For the 5-year period, Seres Therapeutics' Shares Outstanding (Diluted Average) averaged around $102.0 million, with its median value being $108.1 million (2022).
  • In the last 5 years, Seres Therapeutics' Shares Outstanding (Diluted Average) skyrocketed by 4074.5% in 2023 and then tumbled by 9419.6% in 2024.
  • Seres Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $91.7 million in 2021, then rose by 17.86% to $108.1 million in 2022, then rose by 18.44% to $128.0 million in 2023, then grew by 21.4% to $155.4 million in 2024, then crashed by 94.39% to $8.7 million in 2025.
  • Its last three reported values are $8.7 million in Q1 2025, $155.4 million for Q4 2024, and $152.6 million during Q3 2024.